65th ASH Annual Meeting & Exposition: 902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy

Symposia: Health Services and Quality Improvement - Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, Clinical Practice (Health Services and Quality), Clinical Research, health disparities research, Diversity, Equity, and Inclusion (DEI)

Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

Moderators:

Adriana C Rossi, MD, MSc, and Edward Cliff, MBBS, MPH, Brigham and Women’s Hospital, Harvard Medical School

Disclosures:

Rossi: JNJ: Consultancy; BMS: Consultancy; Adaptive: Consultancy; Sanofi: Consultancy.

This oral session focuses on different abstracts related to CAR-T therapy. 2 abstracts evaluate outpatient management of CAR-T therapy and its related complications. 2 abstracts look at cost of CAR-T therapy and 1 of these looks at low cost CAR-T therapy in LMIC. One abstract evaluates access to CAR-T based on insurance type and provides insight into accessing this scarce resource. The reviewing team felt these abstracts provide broad overview of some of the major challenges for patients hoping to receive CAR-T therapy.

2:00 PM

253

Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

Radhika Bansal, MBBS¹^*, Jonas Paludo, MD², Andre Corraes, MD²^*, Megan Spychalla²^*, Kelsey Haugen²^*, Arushi Khurana, MBBS², Paul J. Hampel, MD², Urshila Durani, MD, MPH³, David Dingli, MD², Suzanne R. Hayman, MD², Prashant Kapoor, MD², Yucai Wang, MD, PhD³, Moritz Binder, MD², Saad S. Kenderian, MD³, Taxiarchis Kourelis, MD³, Shaji Kunnathu Kumar, MD³, Rahma M Warsame, MD⁴, N. Nora Bennani, MD², Morie A. Gertz, MD⁵, Patrick B Johnston, MD, PhD³^*, Stephen M Ansell, MD, PhD³ and Yi Lin, MD, PhD¹

¹Mayo Clinic Cancer Center, Rochester, MN
²Mayo Clinic, Rochester, MN
³Division of Hematology, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
⁵Department of Medicine, Division of Hematology,, Mayo Clinic, Rochester, MN

2:15 PM

254

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Tonya Cox, BSN¹, Nicole Zahradka, PhD²^*, Rocky L. Billups, MS¹, Betsy Blunk¹^*, Rebecca Campo³^*, Trista Carelock³^*, Mary Husband⁴^*, Charles F. LeMaistre, MD¹, Navneet Majhail, MD, MS, FASTCT¹, Casey Martin⁵^*, Sarah Meissner⁶^*, Jeremy Pantin, MBBS⁴, Meredith Perez⁴^*, Juliana Pugmire, DrPH²^*, Aravind Ramakrishnan, M.D.⁷, Paul Shaughnessy, MD⁸, Ashleigh Smith⁷^*, Michael T. Tees, MD³, Matt Wilkes, MD, PhD²^*, Megan Yates⁸^* and Minoo Battiwalla, MD⁴

¹Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN
²Current Health, Inc., Boston, MA
³The Colorado Blood Cancer Institute a part of Sarah Cannon Cancer Institute at Presbyterian/St Luke's Medical Center, Denver, CO
⁴Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, Nashville, TN
⁵Genospace, Boston, MA
⁶The Colorado Blood Cancer Institute a part of the Sarah Cannon Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO
⁷Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, Austin, TX
⁸Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, TX

2:30 PM

255

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients

Patrick Connor Johnson, MD¹, Tejaswini Dhawale, MD²^*, Richard Newcomb, MD²^*, Anna Barata²^*, Kyle Karpinski²^*, Mitchell Lavoie³^*, Dagny Vaughn, MS⁴, Kathleen Hennessey²^*, David Scheider, B.S.²^*, Hermioni L Amonoo, MD⁵, Angelo Volandes, M.D., M.P.H.²^* and Areej El-Jawahri, MD²

¹Cancer Center, Massachusetts General Hospital, Boston, MA
²Massachusetts General Hospital, Boston, MA
³University of Massachusetts Chan Medical School, Worchester, MA
⁴University of Tennessee Health Science Center College of Medicine, Memphis, TN
⁵Dana-Farber Cancer Institute, Boston, MA

2:45 PM

256

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Meng-Hsuan Lin, PharmD¹^*, Jonathan Weiss, MD², Tycel J. Phillips, MD³, Dahlia Sano, MD², Shannon A. Carty, MD², Monalisa Ghosh, MD², Iman Ahmed, PharmD²^*, Victoria Nachar, PharmD²^*, David Hutton, Ph.D¹^* and Yasmin H. Karimi, MD²

¹School of Public Health, University of Michigan, Ann Arbor, MI
²Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
³City of Hope, Pasadena, CA

3:00 PM

257

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Atharva Karulkar¹^*, Ankesh Kumar Jaiswal²^*, Aalia Khan²^*, Devanshi Kalra¹^*, Smrithi Ravikumar¹^*, Netra Ghandade¹^*, Ruchira Patil¹^*, Shreshtha Shah¹^*, Afrin Firfiray¹^*, Juber Pendhari²^*, Rushikesh Patil, PhD¹^*, Manivasagam S¹^*, Jayshree Thorat, MD¹^*, Neha Sharma³^*, Alok Shetty, MD, DM⁴^*, Thomas Eipe, PharmD⁵^*, Lingaraj Nayak, MBBS, MD, DM⁴^*, Bhausaheb Bagal, MD, DM⁴^*, Manju Sengar, MD, DM⁶, Gaurav Narula, MD⁶^*, Nirali N. Shah, M.D.⁷, Sattva S. Neelapu, MD⁸, Hasmukh Jain, MD, DM⁶^* and Rahul Purwar, PhD¹^*

¹Immunoadoptive Cell Therapy Private Limited, Mumbai, India
²Department of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Mumbai, India
³Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India
⁴Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
⁵Department of Clinical Pharmacology, Tata Memorial Centre, Mumbai, India
⁶Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
⁷Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD
⁸Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

3:15 PM

258

Patients with Private Insurance Endure Significantly Longer Delays in Time from Intent to CAR-T to Apheresis (Brain-2-Vein) in Multiple Treated Diffuse Large B-Cell Lymphoma: Analysis By Cellular Therapy Intent Quotient (CTIQ)

Matthew Gromowsky¹, Valerie Shostrom²^*, Kimberly Schmidt-pokorny³^*, James Olen Armitage, MD¹, Julie M. Vose, MD, MBA¹, Robert Gregory Bociek, MD, MSc¹, Christopher D’Angelo, MD¹^* and Matthew A. Lunning, DO, FACP^4,5^*

¹University of Nebraska Medical Center, Omaha, NE
²UNMC, Omaha, NE
³Nebraska Medicine, Omaha, NE
⁴Fred and Pamela Buffett Cancer Center/Division of Hematology and Oncology/Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
⁵Heme/Onc, University of Nebraska, Omaha, NE

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.O3.6 902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy